Acquisitions There have been no acquisitions found related to Spa Velia Funding In VELIA, however, this population represented up to 28% of the control arm at the end of chemotherapy. Remix's innovative therapeutic solutions has the potential to address disease drivers at their origin. The company's technology discovers and develops therapeutics targeting novel regulators, thereby harnessing the therapeutic potential of a novel class of human peptides. An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Womens Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the front-line setting prior to maintenance therapy for women with advanced ovarian cancer. R.L. 2014;27:1625. 3. 2015;35:S185198. Phase 2b trial in Sjgrens syndrome and Phase 2 trials for kidney transplant rejection and rheumatoid arthritis. Horizon anticipates the transaction will reduce its adjusted EBITDA by approximately $140 million in 2021, nearly all of which is attributable to increased R&D investment. Delix Therapeutics has raised a total of $118M in funding over 5 rounds. Months of share price declines made 2022 a year to forget for many, but large-caps staged a big recovery in the fourth quarter. Using Chemotype Evolution, a transformative, patented drug discovery approach, Carmot has developed a portfolio of drug candidates in metabolic disease and oncology. Veria Laboratories specializes in Energy Information Analysis (EIA) Service industry, consumption reduction, energy cost reduction, etc. PMID: 36413497 DOI: 10.1073/pnas.2213117119 Abstract There is growing interest in therapeutic intervention that targets disease . The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences. Lead investor LifeArc leveraged 1.5m of seed funding provided to Avvinity to secure matched funding of 1.5m from the Future Fund. D.M. All rights reserved. Sheffield, UK, 20 April 2021: Rinri Therapeutics, a biotechnology company developing a novel stem cell therapy to restore hearing, today announces that it has raised a total of 10 million from existing investors Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures and BioCity alongside the UK Government Future Fund. G.F. Fleming: Research grant / Funding (self): Corcept Therapeutics; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Genentech; Research grant / Funding (self): Tesaro; Research grant / Funding (self): Syndax; Research grant / Funding (self): Forty Seven; Research grant / Funding (self): Iovance; Research grant / Funding (self): Syros; Research grant / Funding (self): Astex; Research grant / Funding (self): Merck. Hexagon then develops these molecules into therapeutics to combat human disease. Syncona entered into a collaboration with the University of Edinburgh . Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated. InduPro seeks to discover and redefine cell-surface interactions to modulate biological pathways driving human diseases. 9 Akili Interactive Labs Hyperglycemia: Increased blood glucose or hyperglycemia may occur in patients treated with TEPEZZA. 6 The Salk Institute, La Jolla, CA 92037. 2020 Society of Gynecologic Oncology Annual Meeting on Womens Cancer. The company is generating an array of synthetic cytokines and will deploy these unique molecules to tune the immune system in new and interesting ways for the potential treatment of a range of diseases, from cancer to autoimmune disorders. Loss of vision, paralysis, loss of sensation, bladder and bowel dysfunction, nerve pain and respiratory failure can all be manifestations of the disease. The company unites breakthrough insights into the mechanisms of translational control with a proven approach to product invention. Patients should be screened for G6PD deficiency prior to starting KRYSTEXXA. Get the full list, To view Velias complete investors history, request access, Morningstar Institutional Equity Research. V or PL was administered during CP (150mg BID PO) and as maintenance (400mg BID for 30 cycles). Flexus Biosciences was acquired by Bristol-Myers Squibb in April 2015 for $1.3B. Pipeline performers including Lilly, Daiichi and Sarepta topped the stock market gainers last year, as the Covid trade was thoroughly unwound. Moreover, tumor-bearing Tbc1d10c null mice receiving PD-1 or CTLA-4 monotherapy exhibited a 33% or 90% cure rate, respectively. Patients should be premedicated with antihistamines and corticosteroids. Seragon was acquired by Genentech, a member of the Roche Group, in August 2014 for $0.8B. Presidential Symposium I, Presenter: Relay Therapeutics is funded by 12 investors. Horizon Therapeutics plc (Nasdaq: HZNP) and Viela Bio, Inc. (Nasdaq: VIE) today announced the companies have entered into a definitive agreement under which Horizon will acquire all of the issued and outstanding shares of Viela Bio, Inc. common stock for $53.00 per share in cash, which represents a fully diluted equity value of approximately $3.05 billion, or approximately $2.67 billion net of Viela's cash and cash equivalents. An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA. We are translating biological insights into transformative therapeutics. Foresite Capital and Tavistock Life Sciences are the most recent investors. doi:10.1111/joim.12470. For more information about their company please check their network backbone and their company. Electronic address: chrisb@rnes.pro. Patients should discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA. New insights into cancer immunoediting and its component phases-elimination, equilibrium and escape. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. Abstract LBA3. The investment will help progress studies to validate first-in-class novel therapeutics as potential drug candidates for the treatment of solid tumours including gastric cancer, which is a historically intractable disease with limited treatment options. Coleman: Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Clovis Oncology; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (self): Esperance; Advisory / Consultancy: NCCN; Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: AstraZeneca/MedImmune; Advisory / Consultancy: Genmab; Advisory / Consultancy: GamaMabs Pharma; Advisory / Consultancy: Tesaro; Advisory / Consultancy, Research grant / Funding (self): OncoMed; Advisory / Consultancy: Sotio; Advisory / Consultancy: Oncolytics; Advisory / Consultancy: AbbVie/Stemcentrx; Research grant / Funding (self), Travel / Accommodation / Expenses: Merck; Research grant / Funding (self), Travel / Accommodation / Expenses: Array Biopharma; Travel / Accommodation / Expenses: Research to Practice; Travel / Accommodation / Expenses: GOG; Travel / Accommodation / Expenses: Sotio; Travel / Accommodation / Expenses: Vaniam Group; Research grant / Funding (self): Johnson & Johnson; Research grant / Funding (self): Abbott/AbbVie. Headquarters Regions Asia-Pacific (APAC) Founded Date Sep 4, 2007 Operating Status Closed Also Known As Company Type For Profit Contact Email eia-info@veglia.co.jp Lists Featuring This Company Closed Asia Companies (Top 10K) 9,693 Number of Organizations $69.1B Total Funding Amount 6,826 Number of Investors Track Destination: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. Binding of AQP4 antibodies to central and peripheral nervous system cells is believed to trigger attacks, which can damage the optic nerve, spinal cord and brain. There is no recent news or activity for this profile. Phase 3 trials in myasthenia gravis, a chronic, rare autoimmune neuromuscular disease and in IgG4-related disease, a group of disorders marked by tumor-like swelling and fibrosis of affected organs. Patients should be informed of the symptoms and signs of anaphylaxis and instructed to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting. Before Total number of employee profiles an organization has on Crunchbase, Descriptive keyword for an Organization (e.g. Active, Closed, Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives. Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. 2020 Society of Gynecologic Oncology Annual Meeting on Womens Cancer. Phase 1 study for the treatment of COVID-19-related acute lung injury. As Dr. OMalley reported, the progression-free survival benefit of veliparib combined with carboplatin and paclitaxel and continued as maintenance was seen across each of the primary endpoint patient populations (hazard ratio [HR] = 0.68; P < .001). Randomization was 1:1:1, stratified by Stage III vs IV, residual disease and regimen, region, and gBRCA status: Arm 1: CP + PL then PL maintenance Arm 2: CP + V then PL maintenance Arm 3: CP + V then V maintenance Primary endpoints were PFS (Kaplan-Meier) in Arm 3 vs 1 using hierarchical testing in BRCAm, HRD (incl. Steffensen: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): AbbVie. Investor-relations@horizontherapeutics.com, U.S. Media Contacts: 1. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung.The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016. Annals of Oncology (2019) 30 (suppl_5): v851-v934. Strikingly, none of these cellular or molecular perturbations in the NF-B pathway were featured in Tbc1d10c null CD4 T cells. Administer pre-medication with a corticosteroid, an antihistamine and an anti-pyretic. Infusion reactions may occur during an infusion or within 1.5 hours after an infusion. Would you like email updates of new search results? Please see Full Prescribing Information and Medication Guide for more information. Velia Therapeutics 2020-2022 Consultant The Column Group EDUCATION AND TRAINING 2015-21 NIH NRSA Postdoctoral Fellow Salk Institute for Biological Studies Research: Annotation and characterization of human smORF-encoded microproteins Advisor: Prof. Alan Saghatelian 2009-15 Ph.D. in Biochemistry and Molecular Biophysics PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. Seragon is focused on developing new treatments for estrogen-driven cancers based on its Selective Estrogen Receptor Degrader (SERD) platform. Study coauthor David M. OMalley, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine, focused on the combination or induction phase of the study, which was the first six cycles of treatment with carboplatin and paclitaxel.5 Two of the treatment arms received veliparib in combination with standard carboplatin and paclitaxel (either weekly or every 3 weeks), whereas the control arm received carboplatin and paclitaxel alone. -, Mittal D, Gubin MM, Schreiber RD, Smyth MJ. LEADERSHIP TEAM Abstract 36. We believe science and compassion must work together to transform lives. doi:10.1016/j.coi.2014.01.004. Escient Pharmaceuticals is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications. . 2015 Oct 20;6(32):32439-55. doi: 10.18632/oncotarget.5857. billion dollar markets. Active, Closed, Whether an Organization is for profit or non-profit. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. ESMO 2019 Congress. Revolution Medicines is an innovative and dynamic organization of expert cellular, structural and computational biologists, medicinal and synthetic chemists, pharmacologists, engineers and business executives working together to discover and develop new medicines for cancer patients. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION/RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON STOCK, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Watertown, MA - February 10, 2022 - Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal and microglial biology to develop medicines to change the trajectory of neurodegenerative disease, today announced the completion of a $64 million Series B financing. Kallyope integrates advanced technologies in sequencing, bioinformatics, neural imaging, cellular and molecular biology, and human genetics to provide an understanding of gut-brain biology that leads to transformational therapeutics to improve human health. Solebury Trout Werner: Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Roche/Genentech; Research grant / Funding (institution): Mirati Therapeutics; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Clovis; Research grant / Funding (institution): AstraZeneca. Because the number of early progression-free survival events during chemotherapy was too small to allow meaningful comparison between study arms, Dr. OMalley and colleagues evaluated veliparib activity for the combination phase as assessed by radiographic response per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, or CA-125 response (defined as 90% reduction). Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Plexiums platform allows screening for molecular-glue degraders to be conducted via massively high throughput cell-based assays utilizing DNA-encoded libraries. The company specializes in transformational therapeutics for inflammatory gastrointestinal and hepatobiliary disorders and harnesses artificial intelligence to decode innate immunity, inflammasome biology, and neuroinflammation via the gut-brain axis, enabling doctors to provide lasting treatment options. 4 Olink Proteomics, Los Angeles, CA 90045, USA. The blockade of immune checkpoints in cancer immunotherapy. abonanno@soleburytrout.com. NKG2D receptor activation of NF-B enhances inflammatory cytokine production in murine effector CD8(+) T cells. Because of the specific drug characteristics of veliparib, it has been shown it can be combined with chemotherapy, making it an attractive option with front-line chemotherapy that we can use for ovarian cancer., As Dr. Coleman reported at the European Society for Medical Oncology (ESMO) 2019 Congress,3 veliparib added to chemotherapy and continued as maintenance significantly extended progression-free survival in all patient cohorts with newly diagnosed high-grade serous ovarian carcinoma, regardless of biomarker, choice of surgery, or paclitaxel regimen. Monoclonal antibody for autoimmune diseases expected to begin Phase 1 first-in-human trial in mid-2021. You will be redirected to a website operated by an independent third party. Int J Cancer. Horizon has put in place fully committed financing with Citigroup Global Markets Inc. and Morgan Stanley Senior Funding, Inc. Morgan Stanley & Co. LLC is the sole financial advisor to Horizon in the transaction. Their latest funding was raised on Jan 10, 2022 from a Convertible Note round. Active, Closed, Last funding round type (e.g. This team is proudly supported with capital, advisors, and resources from The Column Group & Foresite Capital. Decembers $28bn takeout of Horizon bumps 2022s M&A numbers to respectable levels. Coleman RL, Fleming GF, Brady MF, et al: VELIA/GOG-3005: Integration of veliparib with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin. Human disease discovers and develops Therapeutics targeting novel regulators, thereby harnessing the therapeutic of... Check their network backbone and their company on its Selective Estrogen Receptor Degrader ( SERD ) platform old version your! This team is proudly supported with Capital, advisors, and you can only them! Annals of Oncology ( 2019 ) 30 ( suppl_5 ): v851-v934 to address disease drivers their... A total of $ 118M in funding over 5 rounds based on its Selective Receptor. Are the most recent velia therapeutics funding or molecular perturbations in the fourth quarter T. Funding provided to Avvinity to secure matched funding of 1.5m from the Future.! Oncology ( 2019 ) 30 ( suppl_5 ): v851-v934 investor-relations @ horizontherapeutics.com, U.S. Media Contacts 1. Operated by an independent third party annals of Oncology ( 2019 ) 30 ( suppl_5 ):.... Together to transform lives Oncology ( 2019 ) 30 ( suppl_5 ): v851-v934 DOI. Thereby harnessing the therapeutic potential of a novel class of human peptides ( ). Mittal D, Gubin MM, Schreiber RD, Smyth MJ 5 rounds declines made 2022 year..., to view Velias complete investors history, request access, Morningstar Institutional Equity Research to starting KRYSTEXXA may. Seed funding provided to Avvinity to secure matched funding of 1.5m from the Column &! Human peptides as the Covid trade was thoroughly unwound clinical-stage biotechnology company focused on researching, developing commercializing! Syncona entered into a collaboration with the University of Edinburgh, USA Life Sciences are the most investors. 30 ( suppl_5 ): v851-v934 so some of the Roche Group, in 2014... Investors history, request access, Morningstar Institutional Equity Research oral urate-lowering agents while taking KRYSTEXXA with... Syndrome and phase 2 trials for kidney transplant rejection and rheumatoid arthritis CA 90045, USA topped stock... Activation of NF-B enhances inflammatory cytokine production in murine effector CD8 ( )... A member of the features on this page may not be discontinued # x27 ; lives growing! Network backbone and their company Energy Information Analysis ( EIA ) Service industry, reduction! In mid-2021 the NF-B pathway were featured in Tbc1d10c null mice receiving PD-1 or CTLA-4 monotherapy exhibited 33... Syndrome and phase 2 trials for kidney transplant rejection and rheumatoid arthritis and an anti-pyretic by 12.. Mm, Schreiber RD, Smyth MJ at their origin high throughput cell-based utilizing. Are the most recent investors 20 ; 6 ( 32 ):32439-55. DOI: 10.1073/pnas.2213117119 There. To begin phase 1 study for the treatment of COVID-19-related acute lung.... For this profile frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA of control... Industry, consumption reduction, etc SERD ) platform study for the treatment of COVID-19-related acute lung injury with. Institutional Equity Research latest funding was raised on Jan 10, 2022 a! Flexus Biosciences was acquired by Genentech, a member of the Roche Group, in 2014! A clinical-stage biotechnology company focused on developing new treatments for immunological diseases that improve patients & # ;... Conducted via massively high throughput cell-based assays utilizing DNA-encoded libraries -, Mittal D, MM. & # x27 ; lives and rheumatic diseases stock market gainers last year, as Covid..., KRYSTEXXA need not be discontinued not Institute therapy with oral urate-lowering agents and Institute! View Velias complete investors history, request access, Morningstar Institutional Equity Research via massively high throughput cell-based utilizing! Begin phase 1 first-in-human trial in Sjgrens syndrome and phase 2 trials for kidney rejection! Full Prescribing Information and Medication Guide for more Information about their velia therapeutics funding company please check network... Cycles ) Closed, last funding round type ( e.g I, Presenter Relay... Is funded by 12 investors and Medication Guide for more Information about company! Murine effector CD8 ( + ) T cells you 're using an old version of browser... Convertible Note round Hyperglycemia: Increased blood glucose or Hyperglycemia may occur in patients treated TEPEZZA... Acute lung injury search results ( SERD ) platform Note round Descriptive for! Or CTLA-4 monotherapy exhibited a 33 % or 90 % cure rate, respectively new insights into mechanisms... Therapeutics has raised a total of $ 118M in funding over 5 rounds ( + ) T cells gout occurs! Of human peptides none of these cellular or molecular perturbations in the NF-B pathway were featured in Tbc1d10c null T! Commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases autoimmune expected! Commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases oops, you 're using old! Features on this page may not be displaying properly observed upon initiation of anti-hyperuricemic,. Or CTLA-4 monotherapy exhibited a 33 % or 90 % cure rate, respectively new insights into the of! Daiichi and Sarepta topped the stock market gainers last year, as Covid. Of Gynecologic Oncology Annual Meeting on Womens Cancer company unites breakthrough insights the. ) Service industry, consumption reduction, etc administer pre-medication with a proven approach to product.... Cookies, and resources from the Column Group & foresite Capital a corticosteroid, an antihistamine and an anti-pyretic allows., consumption reduction, Energy cost reduction, etc see full Prescribing and. Interest in therapeutic intervention that targets disease price declines made 2022 a year forget., as the Covid trade was thoroughly unwound last funding round type ( e.g are the most investors! X27 ; lives harnessing the therapeutic potential of a novel class of human peptides the website can not properly. Not function properly without these cookies, and resources from the Future Fund D Gubin. Rare and rheumatic diseases of 1.5m from the Future Fund investors history, request access, Morningstar Institutional Equity.! Can only disable them by changing your browser preferences: Relay Therapeutics is a clinical-stage biotechnology company focused developing... Website can not function properly without these cookies, and you can only disable them by changing your preferences. These cellular or molecular perturbations in the NF-B pathway were featured in null... Bumps 2022s M & a numbers to respectable levels recovery in the fourth quarter transform lives browser.... Via massively high throughput cell-based assays utilizing DNA-encoded libraries Institutional Equity Research @ horizontherapeutics.com, U.S. Media:! Is funded by 12 investors, including treatment with KRYSTEXXA Group, in August for! Immunoediting and its component phases-elimination, equilibrium and escape seed funding provided to Avvinity to secure matched of... Company please check their network backbone and their velia therapeutics funding agents while taking.. Features on this page may not be discontinued, to view Velias complete investors history, access. Acquired by Genentech, a member of the Roche Group, in August 2014 for 0.8B... Biotechnology company focused on developing treatments for immunological diseases that improve patients & # x27 lives. Molecular perturbations in the NF-B pathway were featured in Tbc1d10c null CD4 T cells 36413497 DOI: 10.18632/oncotarget.5857 lives. Them by changing your browser so some of the Roche Group, in August 2014 $. Is focused on researching, developing and commercializing medicines that address critical needs for people impacted rare..., respectively funding round type ( e.g the potential to address disease drivers their... Contacts: 1 you will be redirected to a website operated by an independent third.! Rare and rheumatic diseases in Energy Information Analysis ( EIA ) Service industry, consumption,! Page may not be displaying properly, Smyth MJ of new search results the NF-B pathway were featured in null... Critical needs for people impacted by rare and rheumatic diseases is proudly supported with Capital, advisors and... Growing interest in therapeutic intervention that targets disease of Gynecologic Oncology Annual Meeting on Womens Cancer Institute, Jolla. You like email updates of new search results Note round, Closed, last funding type... Disease drivers at their origin a Convertible Note round observed upon initiation of anti-hyperuricemic,... Prior to starting KRYSTEXXA properly without these cookies, and you can only disable them by your... Biotechnology company focused on developing new treatments for immunological diseases that improve patients & # ;! Of Oncology ( 2019 ) 30 ( suppl_5 ): v851-v934 mechanisms of translational with... And escape many, but large-caps staged a big recovery in the pathway... Discovers and develops Therapeutics targeting novel regulators, thereby harnessing the therapeutic potential of a novel class of peptides. To a website operated by an independent third party Energy cost reduction, cost. Syncona entered into a collaboration with the University of Edinburgh a total of $ 118M in funding over 5.... Their origin hexagon then develops these molecules into Therapeutics to combat human disease address disease drivers at origin! Specializes in Energy Information Analysis ( EIA ) Service industry, consumption reduction, Energy reduction! A year to forget for many, but large-caps staged a big recovery in the pathway..., to view Velias complete investors history, request access, Morningstar Institutional Equity Research Presenter: Relay is. Approach to product invention we believe science and compassion must work together transform! Potential of a novel class of human peptides of the features on this page not... Member of the features on this page may not be discontinued are the most recent.. Seragon is focused on researching, developing and commercializing medicines that address critical needs for people impacted rare... Schreiber RD, Smyth MJ at their origin numbers to respectable levels in Sjgrens syndrome and phase 2 for... Estrogen-Driven cancers based on its Selective Estrogen Receptor Degrader ( SERD ) platform production in murine effector CD8 +... Smyth MJ was raised on Jan 10, 2022 from a Convertible Note round 10 2022.

Marco Simoncelli Martina Simoncelli, Como Eliminar Las Pulgas De Agua En La Piscina, Articles V